Evidence map›Paper›PMID 40395325›Full record

ArticleFrontiers in oncology2025

Correlation of heat shock protein 1 expression with progression and prognosis of non-small cell lung cancer.

Rui Wang, Rongqi Guo, Tianyi Huang, Yu Lu, Weisong Zhang, Yihao Wang, Qinggan Ni, Jianxiang Song, Xia Li

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rui Wang *Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
Rongqi Guo *Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
Tianyi Huang *Medical College of Nantong University, Nantong, Jiangsu, China.
Yu LuMedical College of Nantong University, Nantong, Jiangsu, China.
Weisong ZhangDepartment of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
Yihao WangDepartment of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
Qinggan NiDepartment of Burns and Plastic Surgery, Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, Yancheng, Jiangsu, China.
Jianxiang SongDepartment of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
Xia LiDepartment of General Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To investigate the expression and clinical significance of heat shock protein H1 (HSPH1) in non-small cell lung cancer (NSCLC). To provide new and reliable biomarkers for the treatment of NSCLC. Main methods: Various public databases were used to analyse the molecular characteristics, disease relevance and expression differences of HSPH1 and to investigate the correlation between HSPH1 expression and prognosis in NSCLC patients. MsigDB and Molecular signatures database were used for enrichment analysis. The HSPH1 protein interaction network was constructed using the STRING database. In addition, immune infiltration analysis was performed. Subsequently, the expression levels of HSPH1 in Lung cancer cell lines, human NSCLC tissues and normal tissues were determined using various experiments. Finally, a retrospective analysis was performed to determine whether the expression level of HSPH1 was associated with the clinical characteristics and prognosis of NSCLC patients. Results: The high expression of HSPH1 in NSCLC was significantly correlated with the clinical characteristics and poor prognosis of patients, and it may affect the progression of NSCLC by forming a regulatory network with molecules such as HSPA8, BAG2, etc., and its mechanism may involve the regulation of the P53 signalling pathway, G2M_CHECKPOINT and mTORC1_SGNALING. Experiments confirmed that HSPH1 was also highly expressed in NSCLC tissues and cells. Conclusion: HSPH1 can be used as a potential diagnostic and prognostic marker for NSCLC, and its involvement in NSCLC progression and immune regulation may be one of its therapeutic targets.

Indexed as

bioinformatics analysisbiomarkerHSPH1NSCLCprognosisprogression

Identifiers

PMID40395325
PMCPMC12088961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.